BioLife Solutions (NASDAQ:BLFS) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• BioLife Solutions (NASDAQ:BLFS) has received a sell (D-) rating from Weiss Ratings, reaffirmed in a report published on Wednesday.
• Despite the unfavorable rating from Weiss, other analysts have issued a "buy" rating, with HC Wainwright increasing its target price to $32.00.
• The company reported a quarterly loss of ($0.33) earnings per share, missing analyst estimates, although revenue surpassed expectations at $25.42 million.

BioLife Solutions (NASDAQ:BLFS - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other equities analysts also recently issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. Finally, Stephens began coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $31.29.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS traded up $1.04 during trading on Wednesday, reaching $27.34. The stock had a trading volume of 368,318 shares, compared to its average volume of 467,796. The stock has a market capitalization of $1.31 billion, a PE ratio of -227.81 and a beta of 1.95. BioLife Solutions has a 52 week low of $19.10 and a 52 week high of $29.55. The business's 50-day moving average price is $24.72 and its 200 day moving average price is $23.31.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The business had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. Analysts forecast that BioLife Solutions will post -0.3 EPS for the current year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the transaction, the insider owned 6,707,165 shares in the company, valued at approximately $163,654,826. This trade represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Todd Berard sold 10,000 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $25.53, for a total value of $255,300.00. Following the completion of the sale, the chief marketing officer directly owned 124,618 shares of the company's stock, valued at approximately $3,181,497.54. This trade represents a 7.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,016,883 shares of company stock worth $23,929,762. 2.20% of the stock is owned by insiders.

Institutional Trading of BioLife Solutions

A number of large investors have recently made changes to their positions in the company. Invesco Ltd. raised its stake in BioLife Solutions by 0.8% during the 2nd quarter. Invesco Ltd. now owns 3,580,778 shares of the medical equipment provider's stock worth $77,130,000 after buying an additional 29,724 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in shares of BioLife Solutions in the first quarter worth about $30,789,000. Ameriprise Financial Inc. lifted its holdings in shares of BioLife Solutions by 11.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider's stock valued at $23,271,000 after purchasing an additional 109,959 shares in the last quarter. Palisade Capital Management LP lifted its holdings in shares of BioLife Solutions by 13.7% during the 1st quarter. Palisade Capital Management LP now owns 947,085 shares of the medical equipment provider's stock valued at $21,631,000 after purchasing an additional 113,937 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of BioLife Solutions by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 921,105 shares of the medical equipment provider's stock valued at $19,842,000 after purchasing an additional 33,849 shares during the period. Institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.